Graduate at Medicina from Universidade de São Paulo (1983) and Ph.D. at Clinical Medicine from Universidade Estadual de Campinas (1993). Pos-Graduation at the Academic Haematology and Cytogenetics Department, the Royal Marsden Hospital, the Institute of Cancer Research, the University of London (1997). Has experience in Medicine, focusing on Cancerology, acting on genetic abnormalities, inherited and acquired, in malignant tumours. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The epidermal growth factor receptor (EGFR) is fundamental to the proliferation of HNSCC, and EGFR inhibitors are used as therapeutic agents. EGFR activates STAT3 that leads to the production of inflammatory cytokines (IL1A, IL1B, IL32, and TNFA) and proteins (COX-2 and CCND1), responsible for development and progression of HNSCC. The roles of cancer-associated fibroblasts (CAF), cytotoxi…
Cancer is a major public health problem worldwide and ranks among the leading causes of death. Identifying new agents for the diagnosis and treatment of patients with cancer is highly desirable. For many centuries, metals have been used empirically to treat various diseases. Nowadays, metals and their compounds - stable or radioactive - are rationally applied in both the diagnosis and tre…
Cutaneous melanoma (CM) deserves prominence among tumors due to its high mortality. The success of immunotherapy in patients with CM indicates that the immune system acts in the control of the tumor. Recently, single-base genetic variants (SNVs) in the PD1 pathway were associated with our group with the risk and prognosis of CM. It is quite possible that SNVs in genes of other pathways of…
(Only some records are available in English at this moment)
Melanoma is a type of skin cancer that target melanocytes, appearing in the form of moles, spots or dots, usually in the skin or mucous membranes. Considered the most lethal subtype of skin cancer, melanoma has been raising concerns due to its rapidly growing trend, specially in the West. Melanoma treatment is based on surgical resection, although advanced cancer stages require therapies …
(Only some records are available in English at this moment)
Cutaneous melanoma (CM) deserves prominence among malignant tumors due to its high metastatic potential and therapeutic refractoriness. The Janus kinase/Signal tranducer (JAK/STAT) signaling pathway, with the JAK1, JAK2 and STAT3 proteins, regulates the development, progression and metastatic potential of the tumor. The JAK1, JAK2 and STAT3 proteins are encoded by polymorphic genes in hum…
The metals and their compounds were used empirically in the treatment of diseases for a long time. A continuous effort of the scientific community is dedicated to the search for new compounds with antitumor activity, including metallodrugs. Skin tumors are the most common worldwide, including squamous cell carcinoma (CCEP). The only curative therapy for tumor patients is surgical resectio…
Angiogenesis (AG) is the process of vessels formation. AG is important in the development of hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL). Two key proteins are involved in AG: the "vascular endothelial growth factor" (VEGF) and the "vascular endothelial growth factor receptor 2" (VEGFR2). Such proteins are translated by VEGF and VEGFR2 genes, which are polymor…
(Only some records are available in English at this moment)
Cutaneous melanoma (CM) is a serious public health problem due to its high metastatic potential and high mortality rate. The Janus kinase/signal tranducer (JAK/STAT) signaling pathway regulates the development, progression and metastatic potential of the tumor. The STAT3 protein is encoded by polymorphic genes in humans and thus it is possible for normal individuals to present inherited d…
| 2 / 2 | Ongoing research grants |
| 27 / 14 | Completed research grants |
| 5 / 5 | Ongoing scholarships in Brazil |
| 20 / 10 | Completed scholarships in Brazil |
| 2 / 1 | Completed scholarships abroad |
| 56 / 32 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID